VP Regulatory Affairs
Pardes Biosciences
Michelle Pernice, Pharm.D. is Head of Regulatory Affairs at Pardes Biosciences, a clinical-stage biopharmaceutical company developing a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19). Previously, Michelle was Head of Regulatory Affairs at Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, including multiple global COVID vaccine development partnerships. Prior to Dynavax, Michelle was at Amgen for five years, serving in global and regional regulatory lead roles. Additionally, Michelle co-founded an International Public/Private Partnership in East Africa, and currently serves as a board member for The Greater Contribution, a non-profit organization providing micro-loans to women in Uganda. A native New Yorker, Michelle received her Doctorate of Pharmacy (PharmD) degree from St. John’s University, and completed a post-PharmD Rutgers fellowship in global regulatory affairs at Novartis.
Disclosure information not submitted.
Monday, September 12, 2022
3:30 PM – 4:30 PM MST